Hjem › Alvorlig depressiv lidelse › Connecticut
Alvorlig depressiv lidelse kliniske forsøg i Connecticut
16 studier for Alvorlig depressiv lidelse søger deltagere på steder i Connecticut.
Byer i Connecticut
Officiel studietekst (engelsk)
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- UConn Health Center, Farmington
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 25. sep. 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Connecticut Health Center, Farmington
RekruttererFase 3
Alder 18 til 65 · Alle køn · Opdateret 25. sep. 2026 · NCT05850689A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
RekruttererFase 3
Alder 18 til 85 · Alle køn · Opdateret 25. sep. 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 14. sep. 2026 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Institute of Living, Hartford
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 8. sep. 2026 · NCT07076407A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 6. aug. 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Ct Clinical Research Associates, Cromwell
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 3. aug. 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Connecticut School of Medicine Psychiatry Department, Farmington
RekruttererFase 2
Alder 18 til 64 · Alle køn · Opdateret 3. aug. 2026 · NCT06547489A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New Haven
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT07196501Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT06966401The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
RekruttererFase 2
Alder 21 til 65 · Alle køn · Opdateret 6. maj 2026 · NCT05786066Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Yale University, New Haven
RekruttererFase 1
Alder 18 til 60 · Alle køn · Opdateret 6. maj 2026 · NCT05915013Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Hartford Hospital, Hartford
RekruttererObservationsstudie
Alder 18 til 40 · Alle køn · Opdateret 10. mar. 2026 · NCT06740383Imaging Depression in Parkinson's Disease
- Yale University, New Haven
RekruttererFase 2Frivillige med god helbredstilstand velkomne
Alder 40 til 80 · Alle køn · Opdateret 10. mar. 2026 · NCT06402955Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #122, Cromwell
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 20. jan. 2026 · NCT06633016Study of ALTO-300 in MDD
- Site 214, Norwalk
RekruttererFase 2
Alder 18 til 70 · Alle køn · Opdateret 24. jul. 2025 · NCT05922878Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.